PMID- 15762051
OWN - NLM
STAT- MEDLINE
DCOM- 20050607
LR  - 20220408
IS  - 0391-4097 (Print)
IS  - 0391-4097 (Linking)
VI  - 27
IP  - 10
DP  - 2004 Nov
TI  - Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic 
      activity.
PG  - 982-91
AB  - Thiazolidinediones (TZD) [Troglitazone (TRO), Pioglitazone (PGZ), Rosiglitazone, 
      (RGZ)] are a novel class of antidiabetic drugs for patients with Type-2 diabetes 
      mellitus (T2DM) able to decrease blood glucose, working through a reduction of 
      insulin resistance. The family of TZD exerts its effect specifically bound to 
      peroxisome proliferator-activated receptor y (PPARy). This is a member of the 
      nuclear hormone receptor superfamily of ligand-dependent transcription factors, 
      together with PPARalpha and deltabeta. Although PPARgamma is essentially 
      expressed in adipose tissue, it has also been found in endothelial cells, 
      macrophages, vascular smooth muscle cells, glomerular mesangial cells, hepatic 
      stellate cells and in several cancer cell lines. In these cells, the PPARgamma 
      activation by TZD determines modulatory effects on growth factor release, 
      production of cytokine, cell proliferation and migration, extracellular matrix 
      remodeling and control on cell cycle progression and differentiation. In 
      addition, TZD have been shown to have a potent antioxidant effect. This review, 
      taking a quick look beyond the antidiabetic activity of PPARgamma, shows the 
      dramatic ranging of medical implications that the use of TZD could have 
      modulating the PPARgamma activity in several diseases with a strong social 
      impact, such as insulin resistance syndrome, chronic inflammation, 
      atherosclerosis and cancer.
FAU - Giannini, S
AU  - Giannini S
AD  - Endocrinology Unit, Department of Clinical Pathophysiology, University of 
      Florence, Italy. s.giannini@dfc.unifi.it
FAU - Serio, M
AU  - Serio M
FAU - Galli, A
AU  - Galli A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Blood Glucose)
RN  - 0 (PPAR gamma)
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - Arteriosclerosis/drug therapy/physiopathology
MH  - Blood Glucose/*metabolism
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Chronic Disease
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - Inflammation
MH  - Insulin Resistance
MH  - Liver Diseases/physiopathology
MH  - Neoplasms/drug therapy/physiopathology
MH  - Oxidative Stress
MH  - PPAR gamma/*metabolism/*pharmacology
MH  - Thiazolidinediones/*pharmacology
RF  - 91
EDAT- 2005/03/15 09:00
MHDA- 2005/06/09 09:00
CRDT- 2005/03/15 09:00
PHST- 2005/03/15 09:00 [pubmed]
PHST- 2005/06/09 09:00 [medline]
PHST- 2005/03/15 09:00 [entrez]
AID - 5177 [pii]
AID - 10.1007/BF03347546 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2004 Nov;27(10):982-91. doi: 10.1007/BF03347546.